Vertex (VRTX) CMO sells 2,329 shares in pre-set 10b5-1 trade

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 27, 2026, she sold 2,329 shares of Common Stock at an average price of $450.95 per share. After this transaction, she directly holds 33,076 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating the timing was set in advance.

Insider Trade Summary 10b5-1

Net Seller: 2,329 shares ($1,050,263)

Net Sell 1 txn

Insider Bozic Carmen

Role EVP and CMO

Sold 2,329 shs ($1.05M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,329	$450.95	$1.05M

Holdings After Transaction: Common Stock — 33,076 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,329 shares Sale price: $450.95 per share Shares held after transaction: 33,076 shares +1 more

4 metrics

Shares sold 2,329 shares Open-market sale on March 27, 2026

Sale price $450.95 per share Average price for the reported transaction

Shares held after transaction 33,076 shares Direct ownership following March 27, 2026 sale

Trading plan date November 20, 2025 Entry date of Rule 10b5-1 company-approved plan

Key Terms

Rule 10b5-1, open-market sale, Common Stock

3 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		S(1)		2,329	D	$450.95	33,076	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Carmen Bozic report for VRTX?

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported an open-market sale of company stock. She sold 2,329 shares of Vertex Common Stock in a single transaction, as disclosed in a Form 4 insider trading report filed with regulators.

How many Vertex (VRTX) shares did Carmen Bozic sell and at what price?

Carmen Bozic sold 2,329 shares of Vertex Pharmaceuticals Common Stock at an average price of $450.95 per share. This was an open-market transaction and reflects the actual executed sale price reported in the Form 4 filing.

How many Vertex (VRTX) shares does Carmen Bozic hold after this sale?

After the reported transaction, Carmen Bozic directly holds 33,076 shares of Vertex Pharmaceuticals Common Stock. This post-transaction holding figure comes from the Form 4 and shows her remaining direct ownership following the sale.

Was the VRTX stock sale by Carmen Bozic under a Rule 10b5-1 plan?

Yes. The sale was executed under a company-approved Rule 10b5-1 trading plan entered by Dr. Bozic on November 20, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of trade timing as an indicator of insider sentiment.

What type of security did Carmen Bozic sell in the latest VRTX filing?

Carmen Bozic sold shares of Vertex Pharmaceuticals’ Common Stock. The Form 4 indicates a non-derivative transaction, meaning it involved actual shares rather than options or other derivative securities, and was executed as an open-market sale.